BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23363422)

  • 1. Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer.
    Tsuchikawa T; Hirano S; Tanaka E; Matsumoto J; Kato K; Nakamura T; Ebihara Y; Shichinohe T
    Cancer Sci; 2013 May; 104(5):531-5. PubMed ID: 23363422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
    Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
    Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
    Michelakos T; Cai L; Villani V; Sabbatino F; Kontos F; Fernández-Del Castillo C; Yamada T; Neyaz A; Taylor MS; Deshpande V; Kurokawa T; Ting DT; Qadan M; Weekes CD; Allen JN; Clark JW; Hong TS; Ryan DP; Wo JY; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    J Natl Cancer Inst; 2021 Feb; 113(2):182-191. PubMed ID: 32497200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.
    Okubo S; Suzuki T; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Takahashi S; Kojima M
    Cancer Sci; 2021 Jul; 112(7):2895-2904. PubMed ID: 33931909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma.
    Tsuchikawa T; Miyamoto M; Yamamura Y; Shichinohe T; Hirano S; Kondo S
    Ann Surg Oncol; 2012 May; 19(5):1713-9. PubMed ID: 21822560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.
    Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE
    Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
    Shibuya KC; Goel VK; Xiong W; Sham JG; Pollack SM; Leahy AM; Whiting SH; Yeh MM; Yee C; Riddell SR; Pillarisetty VG
    PLoS One; 2014; 9(5):e96565. PubMed ID: 24794217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Kuwabara S; Tsuchikawa T; Nakamura T; Hatanaka Y; Hatanaka KC; Sasaki K; Ono M; Umemoto K; Suzuki T; Sato O; Hane Y; Nakanishi Y; Asano T; Ebihara Y; Kurashima Y; Noji T; Murakami S; Okamura K; Shichinohe T; Hirano S
    Cancer Sci; 2019 Jun; 110(6):1853-1862. PubMed ID: 30997706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma.
    Fukunaga A; Miyamoto M; Cho Y; Murakami S; Kawarada Y; Oshikiri T; Kato K; Kurokawa T; Suzuoki M; Nakakubo Y; Hiraoka K; Itoh T; Morikawa T; Okushiba S; Kondo S; Katoh H
    Pancreas; 2004 Jan; 28(1):e26-31. PubMed ID: 14707745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma.
    Lundgren S; Elebro J; Heby M; Nodin B; Leandersson K; Micke P; Jirström K; Mezheyeuski A
    Int J Cancer; 2020 Jun; 146(12):3461-3473. PubMed ID: 32129882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
    Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
    Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.
    Coia L; Hoffman J; Scher R; Weese J; Solin L; Weiner L; Eisenberg B; Paul A; Hanks G
    Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):161-7. PubMed ID: 8083109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
    Liang Y; Lü W; Zhang X; Lü B
    Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
    Aguilar LK; Shirley LA; Chung VM; Marsh CL; Walker J; Coyle W; Marx H; Bekaii-Saab T; Lesinski GB; Swanson B; Sanchez D; Manzanera AG; Aguilar-Cordova E; Bloomston M
    Cancer Immunol Immunother; 2015 Jun; 64(6):727-36. PubMed ID: 25795132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory T cells and their prognostic value in hepatopancreatobiliary tumours.
    Ozgur HH; Ercetin AP; Eliyatkin N; Seren A; Kupelioglu A; Ortac R; Diniz G; Aktas S
    Hepatogastroenterology; 2014 Oct; 61(135):1847-51. PubMed ID: 25713876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
    Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression.
    Murakami T; Homma Y; Matsuyama R; Mori R; Miyake K; Tanaka Y; Den K; Nagashima Y; Nakazawa M; Hiroshima Y; Ueda M; Tanaka K; Hoffman RM; Bouvet M; Endo I
    J Surg Oncol; 2017 Sep; 116(3):416-426. PubMed ID: 28608409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.